BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 21, 2004
 |  BioCentury  |  Product Development

Move over - I'll drive

This time it's all about control. The lesson that MedImmune Inc. has taken from its experience in partnering FluMist with Wyeth is written all over last week's deal signing Henry Schein Inc. as the exclusive U.S. distributor for the intranasal influenza vaccine.

WYE (Madison, N.J.) tried to position FluMist as a consumer product and bet - incorrectly - that consumers would pay three times the price just to avoid a shot. MEDI wants to position FluMist as a more efficacious vaccine that gives faster, longer-lasting and broader immunity than conventional flu shots - a proposition that needs to be proven via clinical trials and then sold to the clinical community.

While results of those trials are rolling out over the next few years, the deal with Henry Schein gives MEDI marketing muscle while retaining control. For...

Read the full 678 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >